Communication to Pharmacies: General
- Comunicado a Fin de Emergencia Covid -19 6.15.2023
- COM-2023-001 Summary of Puerto Rico Administrative Order 556
- ACT 142-2020 Emergency Provisional Fill Program coverage during the pre-approval process
- FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years
May 2022 - COM-2022-013-Comunicado MCS a Farmacias sobre uso de Invermectin -versión español
- COM-2022-013-Comunicado MCS a Farmacias sobre uso de Invermectin -versión inglés
- COM-2021 – 59 Operational Guide for the submission of the transaction COVID -19 – Oral antiviral drugs emergency use
- Comunicado a Farmacias Ley -142-2020
- COM-2021-053- LEY NUM. 35 2021
- FDA Expands EUAs of Moderna’s and J&J’s COVID-19 Vaccines
November 2021 - FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age
November 2021 - Prior-authorization for Ivermectin due to Increased Use during COVID-19
September 2021 - Comunicado– Carta Normativa-2021-301-D
April 2021 - COVID-19 Vaccine administration requirements
January 2021 - Billing of Insulins Pens
November 2020 - Educational bulletin of the Pharmacy Audit process
November 2020 - Final Rule Modification of the Requirements for the Use of HIPAA National Council for Prescription Drug Programs (NCPDP) D.0 Standard
October 2020 - Orden Administrativa Núm. 441 del Departamento de Salud de Puerto Rico
April 2020 - Prior-authorization for hydroxychloroquine and chloroquine follow up after FDA’s drug safety communication
April 2020 - Carta de Clarificación- Medicamento Clopidogrel
April 2020 - Orden Administrativa Núm. 435 del Departamento de Salud de Puerto Rico
April 2020 - Recomendaciones de dispensación
April 2020 - Prior-authorization for hydroxychloroquine and chloroquine
April 2020 - Guía operacional sobre el despacho de medicamentos durante el estado de emergencia debido al COVID-19
Marzo 2020 - Entrega de medicamentos durante el estado de emergencia debido al COVID-19 y la Ley Núm. 19-2020
Marzo 2020 - Despacho de Medicamentos en Situaciones de Emergencia y/o durante Estado de Emergencia – Poveedores Puerto Rico
Marzo 2020 - Comunicado para proveedores sobre Emergencia COVID-19
Marzo 2020 - RE: Carta Normativa ASES 19-0305. Política pública de anti-discrimen a beneficiarios por razón de identidad de género, expresión de género u orientación sexual real o percibida, al solicitar o recibir servicios de salud.
Marzo 2019 - RE: ASES Normative Letter 19-0305. Public policy for non-discrimination to beneficiaries by reason of gender identity, expression of gender or real or perceived sexual orientation, when requesting or receiving health services.
March 2019 - Guía Básica a Proveedores para manejo sensible y adecuado al brindar servicios de salud a beneficiarios LGBTT+
March 2019 - Importance of the credentialization of pharmacies – Puerto Rico
February 2019
Communication to Pharmacies: Safety
- FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos
April 2026 - FDA Requires Warning about Vitamin B6 Deficiency and Associated Seizures for Drug Products
March 2026 - FDA Requests Removal of Suicidal Warning from GLP-1 RA Medications
February 2026 - IGIV and IGSC Lots with Increased Reports of Allergic Hypersensitivity Reactions
November 2025 - FDA Recommends Earlier MRI Monitoring for Patients Taking Leqembi
September 2025 - FDA Removes REMS for Clozapine
August 2025 - FDA Update on the Safety of Ixchiq (Chikungunya Vaccine Live)
August 2025 - FDA Requires Labeling Update for Opioids
August 2025
- FDA Requires Expanded Labeling About Weight Loss Risk in Young Patients Taking Stimulants for ADHD
July 2025 - FDA Approves Required Updated Warning in Labeling of mRNA COVID-19 Vaccines
July 2025 - FDA Adds Warning about Heat-Related Complications with Transderm Scop
June 2025 - FDA Requires Warning about Rare Itching with Cetirizine and Levocetirizine
May 2025 - FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live)
May 2025 - FDA Adds Boxed Warning for Glatiramer Acetate
January 2025 - FDA Requires GBS Warning in the Prescribing Information for Abrysvo and Arexvy
January 2025 - Serious Liver Injury in Patients Taking Ocaliva
December 2024 - Rare Occurrence of Serious Liver Injury with Use of Veozah
September 2024 - New Boxed Warning for Prolia regarding Severe Hypocalcemia
January 2024 - Evaluation of Suicidal Thoughts with Type 2 Diabetes and Obesity Drugs
January 2024
Communication to Pharmacies: Education
- FDA Grants Priority Review Vouchers to Psychedelic-Based Therapies
May 2026 - Orforglipron The New Oral Small Molecule GLP1 Agonist
April 2026 - FDA Removes Boxed Warnings from Select HRT
March 2026 - Lung Cancer Leads Mortality Rate
February 2026 - FDA Approves Wegovy Tablets
January 2026 - Label Changes for Menopausal Hormones Therapy
December 2025 - GAD Prevalence Continues to Climb
November 2025 - FDA Approves the First Intranasal Diuretic
October 2025
- Wegovy Receives Accelerated Approval for MASH
September 2025 - FDA Approves Prefilled Shingrix Vaccine
August 2025 - Addressing Misconceptions About Biosimilars
July 2025 - Risk of CVD Increases in Adult-Onset T1D
June 2025 - Semaglutide Shows Improvement in MASH
May 2025 - FDA Approves New UTI Antibiotic
April 2025 - FDA Approves First Novolog Biosimilar
March 2025 - Ozempic Now Approved to Lower Kidney Disease Risk in Type 2 Diabetes
February 2025 - Zepbound Approved for Obese Adults with Sleep Apnea
January 2025 - Semaglutide Improves Liver Fibrosis in New Trial Analysis
December 2024 - FDA Suggests Removing Nonprescription Decongestant from Market
November 2024 - Abrysvo FDA Approved for Adults 18 to 59 Years of Age
November 2024 - Veklury (remdesivir) for Injection by Gilead Sciences, Inc.
September 2024 - First Nasal Spray for the Treatment of Anaphylaxis
September 2024 - FDA Approves a New Alzheimer’s Disease Drug
August 2024 - First Authorized Generic for a GLP-1 Receptor Agonist
July 2024 - First Biosimilars for Eylea
June 2024 - First Therapy for WHIM Syndrome
April 2024 - New Breakthrough Indication for Wegovy
April 2024 - Dupixent Possible Approval for COPD
March 2024 - New Black Box Warning for Prolia
February 2024 - Updates Related to Drug Therapy in Diabetes Guidelines
January 2024
PharmNotes
- April 2026
- March 2026
- February 2026
- January 2026
- December 2025
- November 2025
- October 2025
- September 2025
Recalls
- 20 mEq Potassium Chloride Injection from Otsuka ICU
November 2025 - Cyclobenzaprine Hydrochloride Tablets USP 10 mg by Unichem
September 2025 - Cefazolin Injection 1 gram
July 2025 - Sucralfate Tablets USP 1 gram from Nostrum Labs
July 2025 - Sulfamethoxazole/Trimethoprim Tablets 400 mg/80 mg
June 2025 - Levetiracetam in Sodium Chloride Injection
March 2025 - Fentanyl Transdermal System 25 mcg/h by Alvogen
February 2025 - Tacrolimus and Tacrolimus Extended-Release capsules by Astellas
December 2024
- Clonazepam Orally Disintegrating Tablets, USP_Endo
November 2024 - Veklury (remdesivir) for Injection by Gilead Sciences, Inc.
September 2024 - Atovaquone Oral Suspension by Bionpharma Inc.
September 2024 - Sodium Chloride 0.9%_Braun
August 2024 - Heparin Sodium_Baxter
August 2024 - Acetaminophen Injection_Hikma
July 2024 - Clonazepam ODT 0.25mg_Par Pharma
July 2024 - Potassium Chloride Extended Release 750mg Capsules, USP – American Heath on Behalf Blue Point Lab
June 2024 - Potassium Chloride Extended Release 750mg Capsule
June 2024 - Buprenorphine & Labetalol Injection
May 2024 - Docetaxel Injection
May 2024 - Sapropterin Dihydrochloride Powder for Oral Solution 100mg
April 2024 - Atovaquone Oral Suspension_AvKARE LLC
April 2024 - Methocarbamol 1000mg/10mL Injection
March 2024 - Vancomycin 250mg/5mL Oral Solution
March 2024 - Treprostinil 20mg/20mL Injection_ParPharma
March 2024 - Zenzedi 30mg Tablets
January 2024 - Bleomycin for Injection_Hospira
December 2023 - Sodium Bicarbonate and Atropine for Injection_Hospira
December 2023 - Vigabatrin Oral Solution 500mg/sachet_InvaGen
December 2023 - Sandimmune Oral Solution 100mg/mL_Novartis
November 2023 - Vitrakvi Oral Solution 20mg/mL_Bayer
November 2023 - Sodium Bicarbonate Midazolam and Elcys_Exela Pharma Sciences LLC
October 2023 - Betaxolol Tablets 10mg_KVK-Tech, Inc.
October 2023 - Brexafemme Tablets 150mg_Scynexis
October 2023 - Sucralfate Oral Suspension 1g/10mL_VistaPharm LLC
September 2023 - Sandimmune Oral Solution 100mg/mL_Novartis
September 2023 - Digoxin Tablets 0.125mg and 0.25mg_Marlex Pharmaceuticals Inc.
August 2023 - Tydemy Oral Contraceptive_Lupin Pharmaceuticals
July 2023 - Albuterol Sulfate Inhalation Aerosol_Cipla
July 2023
Join Our Network
- PharmPix Pharmacy Network Request Application
- Exception Request Form
- Important Information About Your Appeal Rights
- Concurrent Utilization Review
- Pharmacy Rights and Responsibilities
- Members Rights and Responsibilities
- Pharmacy and Therapeutics Committee
- Pricing Research Request Form
- Prior Authorization Form
- Retrospective Drug Utilization Review Program
- Universal Claim Form
- Pharmacy Credentialing/ Recredentialing
- PharmPix Pharmacy Network Provider Fraud Waste and Abuse (FWA) and General Compliance Training
- 2025 Fraud, Waste and Abuse (FWA) and General Compliance Training Log
- 2024 Fraud, Waste and Abuse (FWA) and General Compliance Training Log
- Fraud, Waste and/or Abuse Complaint Form
- PharmPix Contact Information
- Provider Complaint Form
- Pharmacy Contracting
- Pharmacy Credentialing Form
- PharmPix Provider Manual